Ertumaxomab
Alternative Names: Anti-CD3 X anti-HER-2/neu; Rexomab®; RexomunLatest Information Update: 02 Oct 2021
At a glance
- Originator TRION Pharma
- Developer Fresenius Biotech; TRION Pharma
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunostimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 14 Aug 2009 Discontinued - Phase-II for Breast cancer in Europe (IV)
- 03 Jun 2008 Pharmacodynamics data from a preclinical study in breast cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
- 12 Jul 2006 Phase-II clinical trials in Breast cancer in Europe (IV-infusion)